生化工程
上游(联网)
生产(经济)
可扩展性
过程(计算)
计算机科学
寡核苷酸
食品药品监督管理局
生物技术
业务
纳米技术
风险分析(工程)
化学
生物
电信
工程类
材料科学
经济
基因
生物化学
数据库
宏观经济学
操作系统
作者
Martina Catani,Chiara De Luca,João Medeiros Garcia Alcântara,Nicolò Manfredini,Daniela Perrone,Elena Marchesi,Richard Weldon,Thomas Müller‐Späth,Alberto Cavazzini,Massimo Morbidelli,Mattia Sponchioni
标识
DOI:10.1002/biot.201900226
摘要
Abstract Oligonucleotides (ONs) are gaining increasing importance as a promising novel class of biopharmaceuticals. Thanks to their fundamental role in gene regulation, they can be used to develop custom‐made drugs (also called N‐to‐1) able to act on the gene expression at pre‐translational level. With recent approvals of ON‐based therapeutics by the Food and Drug Administration (FDA), a growing demand for high‐quality chemically modified ONs is emerging and their market is expected to impressively prosper in the near future. To satisfy this growing market demand, a scalable and economically sustainable ON production is needed. In this paper, the state of the art of the whole ON production process is illustrated with the aim of highlighting the most promising routes toward the auspicated market‐size production. In particular, the most recent advancements in both the upstream stage, mainly based on solid‐phase synthesis and recombinant technology, and the downstream one, focusing on chromatographic techniques, are reviewed. Since ON production is projected to expand to the large scale, automatized multicolumn countercurrent technologies will reasonably be required soon to replace the current ones based on batch single‐column operations. This consideration is supported by a recent cutting‐edge application of continuous chromatography for the ON purification.
科研通智能强力驱动
Strongly Powered by AbleSci AI